



DIVISION OF
**PHARMACOEPIDEMIOLOGY &
PHARMACOECONOMICS**

DEPARTMENT OF MEDICINE
BRIGHAM AND WOMEN'S HOSPITAL
HARVARD MEDICAL SCHOOL



Ameet Sarpatwari, J.D., Ph.D.

Brigham and Women's Hospital
Department of Medicine
Division of Pharmacoepidemiology & Pharmacoeconomics
1620 Tremont Street, Suite 3030,
Boston, MA 02120
asarpatwari@partners.org
Phone: 617-278-0936 | Fax: 617-278-0930



Ameet Sarpatwari is an Instructor in Medicine at Harvard Medical School and an Associate Epidemiologist at Brigham and Women's Hospital based in the Program On Regulation, Therapeutics, And Law (PORTAL) within the Division of Pharmacoepidemiology and Pharmacoeconomics. His research draws upon his interdisciplinary training as an epidemiologist and lawyer and focuses on the effects of laws and regulations on therapeutic development, approval, use, and related public health outcomes. Among other projects, he is currently examining the public health implications of variation in state drug product selection laws, the risk of re-identification under HIPAA pathways for data sharing for post-approval drug research, and the comparative safety and effectiveness of biosimilars.

Dr. Sarpatwari graduated Phi Beta Kappa from the University of Virginia in 2003, where he was a Jefferson Scholar. He studied epidemiology at the University of Cambridge, where he received an M.Phil. in 2006 and a Ph.D. in 2010. His doctoral work centered on uncovering disease progression, treatment effectiveness, and co-morbid burden among adults patients with primary immune thrombocytopenia through the establishment of a national disease registry. He subsequently studied law at the University of Maryland, as a John L. Thomas Leadership Scholar, graduating cum laude in 2013.

Dr. Sarpatwari is currently the Principal Investigator on a Robert Wood Johnson Public Health Law Research grant and a Faculty Affiliate with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Behavioral Insights Group at the Harvard Kennedy School.

Selected Publications | [Current PubMed Search Results](#)

- Avorn J, **Sarpatwari A**, Kesselheim AS. Forbidden and permitted statements in evolution: rules in evolution. *N Engl J Med* 2015. [In press]
- **Sarpatwari A**, Avorn J, Kesselheim AS. [Progress and hurdles for follow-on biologics](#). *N Engl J Med* 2015;372(25):2380-82.

- **Sarpatwari A**, Darrow JJ, Kesselheim AS. [Expanded access to investigational drugs](#). *N Engl J Med* 2015;372(15):1473-74.
- **Sarpatwari A**, Choudhry NK, Avorn J, Kesselheim AS. [Paying physicians to prescribe generic drug and follow-on biologics in the United States](#). *PLoS Med* 2015;12(3):e1001802.
- Darrow JJ, **Sarpatwari A**, Avorn J, Kesselheim AS. [Practical, legal, and ethical issues in expanded access to investigational drugs](#). *N Engl J Med* 2015;372(3):279-86.
- **Sarpatwari A**, Franklin JM, Avorn J, Seeger JD, Landon JE, Kesselheim AS. [Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of ITP](#). *AClin Pharmacol Ther* 2015;97(2):186-93.
- **Sarpatwari A**, Kesselheim AS, Malin B, Gagne JJ, Schneeweiss S. [Ensuring patient privacy in data sharing for postapproval research](#). *N Engl J Med* 2014;371(17):1644-49.
- **Sarpatwari A**, Avorn J, Kesselheim AS. [Using a drug-safety tool to prevent competition](#). *N Engl J Med* 2014;370(16):1476-78.
- **Sarpatwari A**, Robertson CT, Yokum DV, Joiner K. [Crowdsourcing public health experiments: a response to Jonathan Darrow's "Crowdsourcing Clinical Trials"](#). *Minnesota Law Rev* 2014;98:101-20
- **Sarpatwari A**. [Just say no: the case against the reclassification of buprenorphine](#). *Univ Maryland Law J Race Religion Gender & Class* 2012;12:377-95. [Recipient of the Joseph Bernstein Award for the most significant student piece of scholarly writing]
- **Sarpatwari A**, Bussel JB, Erqou S, et al. [Single-nucleotide polymorphism analysis demonstrates a significant association of tumour necrosis factor-alpha \(TNFA\) with primary immune thrombocytopenia](#). *Hematology* 2011;16(4):243-48.
- Anzures-Cabrera J,***Sarpatwari A**,* Higgins JPT.* [Expressing findings from meta-analyses of continuous outcomes in terms of risks](#). *Stat Med* 2011;30(25):2967-85. [*Joint first authors]
- **Sarpatwari A**, Provan D, Erqou S, et al. [Autologous 111In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia \(ITP\) prior to splenectomy: A report from the United Kingdom ITP Registry](#). *Br J Haematol* 2010;151(5):477-87.
- **Sarpatwari A**, Watson S, Erqou S, et al. [Health-related lifestyle in adults and children with primary ITP](#). *Br J Haematol* 2010;151(2):189-91.
- **Sarpatwari A**, Bennett D, Logie JW, et al. [Thromboembolic events among adult patients with primary immune thrombocytopenia \(ITP\) in the United Kingdom General Practice Research Database](#). *Haematologica* 2010;95(7):1167-75.
- **Sarpatwari A**, Segal JB, Bussel JB, Stasi R, Osborn J. [A case of rich fruit](#). *Blood* 2009;113(124):6260.